SHINE Technologies, LLC Announces Submission of FDA Drug Master File for Non-Carrier-Added Lutetium-177

SHINE Technologies, LLC Announces Submission of FDA Drug Master File for Non-Carrier-Added Lutetium-177

Press Releases
SHINE Technologies, LLC Announces Submission of FDA Drug Master File for Non-Carrier-Added Lutetium-177
No items found.

About SHINE Technologies

Headquartered in Janesville, Wisconsin, SHINE Technologies stands as an industry leader in next-generation fusion, deploying innovative fusion technology that seamlessly combines safety, cost-efficiency, and environmental responsibility. SHINE is at the forefront of creating non-carrier-added lutetium-177—a vital component in cutting-edge medical treatments.  

SHINE’s commitment to innovation extends beyond the realms of industry and healthcare. Drawing on its fusion technology expertise, the company has set its sights on addressing one of energy's most complex challenges—nuclear waste recycling and fusion energy. With a comprehensive and visionary approach, SHINE is steadfastly driving advancements across multiple sectors, leaving an indelible mark on the domains of technology, healthcare, and sustainable energy solutions.

Contacts

Tammy Jackson, VP Marketing & Communication, SHINE Technologies

tammyjackson@shinefusion.com

Lutetium-177 Information Sheet (EU Distribution)Ilumira Information Sheetdownload PDF RESOURCE HERE